Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVJF) Leases (2018 - 2025)

Historic Leases for Teva Pharmaceutical Industries (TEVJF) over the last 11 years, with Q4 2025 value amounting to $345.0 million.

  • Teva Pharmaceutical Industries' Leases fell 599.46% to $345.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $345.0 million, marking a year-over-year decrease of 599.46%. This contributed to the annual value of $345.0 million for FY2025, which is 599.46% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Leases of $345.0 million as of Q4 2025, which was down 599.46% from $342.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Leases ranged from a high of $531.0 million in Q2 2021 and a low of $342.0 million during Q3 2025
  • For the 5-year period, Teva Pharmaceutical Industries' Leases averaged around $415.5 million, with its median value being $412.0 million (2023).
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Leases skyrocketed by 58513.51% in 2021, and later plummeted by 1694.92% in 2022.
  • Over the past 5 years, Teva Pharmaceutical Industries' Leases (Quarter) stood at $495.0 million in 2021, then dropped by 15.35% to $419.0 million in 2022, then decreased by 5.25% to $397.0 million in 2023, then fell by 7.56% to $367.0 million in 2024, then decreased by 5.99% to $345.0 million in 2025.
  • Its last three reported values are $345.0 million in Q4 2025, $342.0 million for Q3 2025, and $358.0 million during Q2 2025.